着床前遺伝子検査市場規模、シェア、動向、2030年までの世界予測

着床前遺伝子検査市場 – 製品とサービス（試薬、消耗品、機器、ソフトウェア）、テクノロジー（NGS、PCR、SNP、CGH）、手順（スクリーニング、診断）、用途（異数性、HLAタイピング）、サイクルの種類 – 2030年までの世界予測

着床前遺伝子検査市場は、2025年の6億9,020万米ドルから2030年には11億3,500万米ドルに達し、予測期間中に10.5%のCAGRで成長すると予想されています。市場の成長は、遺伝性疾患の罹患率の増加、早期遺伝子診断に関する意識の高まり、そして世界中で体外受精（IVF）処置の採用が増えていることが主な要因です。着床前遺伝子検査の需要は、検査の精度と効率を高める次世代シーケンシング（NGS）とポリメラーゼ連鎖反応（PCR）技術の進歩にも支えられています。さらに、妊娠の遅延傾向と受精卵の染色体異常リスクの上昇も市場拡大に貢献しています。しかし、IVFと遺伝子検査の費用の高さ、そして倫理的・規制上の課題が、依然として広範な導入を阻んでいます。

調査対象範囲

本調査レポートでは、着床前遺伝子検査市場を、検査方法（着床前遺伝子スクリーニング、着床前遺伝子診断）、技術（次世代シークエンシング、ポリメラーゼ連鎖反応、蛍光in situハイブリダイゼーション、比較ゲノムハイブリダイゼーション、一塩基多型）、製品・サービス（試薬・消耗品、機器、ソフトウェア・サービス）、用途（異数性、染色体構造異常（転座、欠失、重複、逆位）、単一遺伝子疾患、X連鎖疾患、HLAタイピング、性別判定）、周期の種類（新鮮非ドナー、凍結非ドナー、新鮮ドナー、凍結ドナー）、エンドユーザー（不妊治療クリニック、病院、診断研究所、その他のエンドユーザー）、地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。

本レポートは、着床前遺伝子検査市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの包括的な分析により、各社の事業概要、製品ポートフォリオ、主要戦略、新製品の発売、買収、そして着床前遺伝子検査市場に関連する最近の動向に関する洞察を提供しています。また、本レポートには、着床前遺伝子検査業界のエコシステムにおける新興スタートアップ企業の競合分析も含まれています。

レポート購入の主なメリット

本レポートは、市場全体とそのサブセグメントの収益予測を提供することで、市場リーダー企業と新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、ビジネスを効果的にポジショニングし、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。

本レポートでは、以下の点について洞察を提供しています。

• 市場の成長に影響を与える主要な要因（出生率の低下、新興国における不妊治療ツーリズムの台頭、不妊治療クリニックおよび体外受精センターの増加、新たな診断技術開発への官民投資の増加、高齢化に伴う染色体異常リスクの高まり）、制約要因（着床前遺伝子検査の高額な費用、体外受精に関する政府規制および医療改革）、機会（医療インフラの改善、新興国における医療ツーリズムの増加、シングルペアレントおよび同性カップルによる不妊治療の利用）、課題（着床前遺伝子検査をめぐる社会倫理的な懸念、高齢化に伴う手続き上の制約）の分析
• 製品開発／イノベーション：着床前遺伝子検査市場における新製品と技術評価に関する詳細な洞察
• 市場開発：収益性の高い市場に関する包括的な情報と、様々な地域における市場分析
• 市場多様化：着床前遺伝子検査市場における新製品、未開拓地域、最近の開発状況、投資に関する網羅的な情報
• 競合評価：着床前遺伝子検査市場向けに製品・サービスを提供している主要企業（Illumina, Inc.（米国）、Thermo Fisher Scientific Inc.（米国）、Agilent Technologies, Inc.（米国）、Revvity（米国）、CooperCompanies（米国）、Abbott（米国）など）の市場シェア、成長戦略、製品ラインナップに関する詳細な評価。その他、MedGenome（インド）、Fulgent Genetics（米国）、Invicta（ポーランド）、Genea Pty Limited（オーストラリア）、SciGene Corporation（米国）、Bioarray S.L.など。 （スペイン）、Unimed Biotech（上海）Co., Ltd（中国）、GeneMind Biosciences Co., Ltd.（中国）など、着床前遺伝子検査市場向けの企業

Report Description

The preimplantation genetic testing market is expected to reach USD 1,135.0 million by 2030, up from USD 690.2 million in 2025, at a CAGR of 10.5% during the forecast period. The market growth is primarily driven by the increasing prevalence of genetic disorders, growing awareness regarding early genetic diagnosis, and the rising adoption of in-vitro fertilization (IVF) procedures worldwide. The demand for preimplantation genetic testing is also supported by advancements in next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies that enhance testing accuracy and efficiency. Moreover, the growing trend toward delayed pregnancies and the rising risk of chromosomal abnormalities in embryos are contributing to the market expansion. However, the high costs associated with IVF and genetic testing procedures, along with ethical and regulatory challenges, continue to hinder widespread adoption.

“The aneuploidy application segment is expected to grow at the highest CAGR during the forecast period.”

The aneuploidy application segment is projected to grow at the highest CAGR in the preimplantation genetic testing market during the forecast period. This growth is primarily driven by the rising incidence of chromosomal abnormalities, particularly among women of advanced maternal age, and the increasing demand for accurate embryo screening in IVF procedures. Aneuploidy enables the detection of abnormal chromosome numbers, helping improve implantation rates and reduce the risk of miscarriage. The integration of advanced genomic tools such as next-generation sequencing (NGS) and array-based comparative genomic hybridization (aCGH) has further enhanced test precision and efficiency. Additionally, growing awareness of genetic screening benefits and the rising adoption of assisted reproductive technologies are contributing to the strong growth of the aneuploidy segment globally.

“The reagents and consumables segment holds the largest share of the market.”

The reagents and consumables segment holds the largest share of the preimplantation genetic testing market. This dominance is due to their repeated use at every stage of the testing process, including sample preparation, amplification, and analysis. The increasing number of IVF procedures and genetic tests has greatly boosted the demand for high-quality reagents, assay kits, and consumables that provide accuracy, reproducibility, and consistent results. Additionally, advances in next-generation sequencing (NGS), polymerase chain reaction (PCR), and array-based platforms have enabled the development of specialized reagents for high-throughput and precise embryo analysis. Ongoing product innovations by major market players, along with the growing use of genetic screening in fertility clinics and research labs, further drive segment growth. The essential and recurring nature of these products secures their leading role in the global preimplantation genetic testing market.

“The US is expected to grow at the highest CAGR during the forecast period.”

The US is expected to have the highest growth rate in the preimplantation genetic testing market, driven by several key factors. The strong presence of leading IVF clinics, advanced genomic labs, and a well-established healthcare system significantly contributes to market growth in the country. Additionally, the increasing rate of infertility, rising average maternal age, and growing awareness of genetic screening options are boosting demand for preimplantation genetic testing in the US. Favorable reimbursement policies, supportive government initiatives for reproductive health, and ongoing investments in genomic research further drive market expansion.

Furthermore, the growing integration of next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies in IVF procedures is improving testing accuracy and efficiency. Increasing access to assisted reproductive technologies, along with the rising preference for personalized reproductive care, continues to drive the adoption of preimplantation genetic testing across the region. The US’s robust regulatory framework ensures test reliability and clinical validity, bolstering confidence in preimplantation genetic testing solutions and reinforcing North America’s leading position in the global market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1 – 25%, Tier 2 – 35%, and Tier 3 – 40%
• By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
• By Region: North America – 35%, Europe – 25%, Asia Pacific – 15%, Latin America – 10%, the Middle East – 10%, and Africa – 5%

Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), CooperCompanies (US), Abbott (US), Takara Bio Inc. (Japan), QIAGEN (Germany), Vitrolife (Sweden), Oxford Nanopore Technologies plc (UK), Oxford Gene Technology IP Limited (UK), Yikon Genomics (China), Shiva Scientific (India), Nanjing Superyears Gene Technology Co. Ltd. (China), Medicover Genetics (Germany), MedGenome (India), Fulgent Genetics (US), Invicta (Poland), Genea Pty Limited (Australia), SciGene Corporation (US), Bioarray S.L. (Spain), Unimed Biotech (Shanghai) Co., Ltd. (China), GeneMind Biosciences Co. Ltd. (China), Berry Genomics (China), and Bangkok Genomics Innovation (Thailand) are some of the key companies offering preimplantation genetic testing products.

Research Coverage

This research report categorizes the preimplantation genetic testing market by procedure type (preimplantation genetic screening, preimplantation genetic diagnosis), technology (next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, single-nucleotide polymorphism), product & service (reagents & consumables, instruments, software & services), application (aneuploidy, structural chromosomal abnormalities [translocations, deletions, duplications, inversions], single gene disorders, X-linked disorders, HLA typing, gender identification), type of cycle (fresh non-donor, frozen non-donor, fresh donor, frozen donor), end user (fertility clinics, hospitals, diagnostic laboratories, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).

The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the preimplantation genetic testing market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the preimplantation genetic testing market. This report also includes a competitive analysis of emerging startups in the preimplantation genetic testing industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market’s pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (decline in fertility, rise of fertility tourism in emerging economies, increasing number of fertility clinics and IVF centers, increasing public-private investments to develop novel diagnostic techniques, and high risk of chromosomal abnormalities with advancing maternal age), restraints (high procedural cost in preimplantation genetic testing and unfavorable government regulations and healthcare reforms for IVF procedures), opportunities (improving healthcare infrastructure and rising medical tourism in emerging economies and use of fertility treatments by single parents and same-sex couples), and challenges (socio-ethical concerns surrounding preimplantation genetic testing and procedural limitations with advancing age) influencing the market growth
• Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the preimplantation genetic testing market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the preimplantation genetic testing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), and Agilent Technologies, Inc. (US), Revvity (US), CooperCompanies (US), and Abbott (US), among others offering products and services for preimplantation genetic testing market. Other companies include MedGenome (India), Fulgent Genetics (US), Invicta (Poland), Genea Pty Limited (Australia), SciGene Corporation (US), Bioarray S.L. (Spain), Unimed Biotech (Shanghai) Co., Ltd (China), and GeneMind Biosciences Co., Ltd. (China), among others, for the preimplantation genetic testing market

Table of Contents

1               INTRODUCTION              36

1.1           STUDY OBJECTIVES       36

1.2           MARKET DEFINITION   36

1.3           STUDY SCOPE   37

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 37

1.3.2        INCLUSIONS & EXCLUSIONS       38

1.3.3        YEARS CONSIDERED      38

1.3.4        CURRENCY CONSIDERED            39

1.4           STAKEHOLDERS               39

1.5           SUMMARY OF CHANGES               39

2               EXECUTIVE SUMMARY  41

2.1           KEY INSIGHTS & MARKET HIGHLIGHTS 41

2.2           KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS              48

2.3           DISRUPTIVE TRENDS SHAPING PREIMPLANTATION GENETIC TESTING MARKET       49

2.4           HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS                 49

2.5           GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT       50

3               PREMIUM INSIGHTS       51

3.1           NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE AND COUNTRY                 51

3.2           PREIMPLANTATION GENETIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES            52

3.3          PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY PRODUCT &

SERVICE, 2025 VS. 2030 (%)           53

3.4          PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY END USER, 2024 (%)  53

4               MARKET OVERVIEW       54

4.1           INTRODUCTION              54

4.2           MARKET DYNAMICS       54

4.2.1        DRIVERS               55

4.2.1.1    Decline in fertility rates       55

4.2.1.2    Expanding network of fertility clinics and IVF centers   56

4.2.1.3    Rising incidence of chromosomal abnormalities associated with advancing maternal age       56

4.2.2        RESTRAINTS      57

4.2.2.1    High procedural cost            57

4.2.2.2    Stringent regulatory frameworks governing IVF and genetic testing procedures                57

4.2.3        OPPORTUNITIES              58

4.2.3.1    Expanding acceptance of fertility treatments among single parents and same-sex couples             58

4.2.4        CHALLENGES    58

4.2.4.1    Socio-ethical concerns regarding embryo screening and selection                 58

4.3           UNMET NEEDS & WHITE SPACES              59

4.4           INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES              59

4.5           STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS       60

5               INDUSTRY TRENDS         62

5.1           TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            62

5.2           MACROECONOMIC OUTLOOK  62

5.2.1        GDP TRENDS & FORECAST          63

5.2.2        R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY                 63

5.2.3        R&D TRENDS IN GLOBAL PHARMA INDUSTRY   63

5.3           CASE STUDY ANALYSIS 64

5.3.1        PGT-M FOR RPGRIP1L VARIANT-ENABLED BY MINIGENE ASSAY             64

5.3.2        PERSISTENT FETAL MOSAICISM AFTER TRANSFER OF PGT-A MOSAIC EMBRYO               64

5.3.3        CRYPTIC REARRANGEMENTS RESOLVED BY OGM TO GUIDE PGT-SR  64

5.4           PRICING ANALYSIS          64

5.4.1        AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY END USER, 2022−2024               65

5.4.2        AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY KEY PLAYER, 2022–2024            65

5.4.3        AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY PROCEDURE TYPE, 2022−2024   67

5.4.4        AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS AND CONSUMABLES, BY REGION, 2022–2024  67

5.5           TRADE ANALYSIS             69

5.5.1        IMPORT DATA FOR HS CODE 3822, 2020–2024      69

5.5.2        EXPORT DATA FOR HS CODE 3822, 2020–2024      70

5.5.3        IMPORT DATA FOR HS CODE 9018, 2020–2024      71

5.5.4        EXPORT DATA FOR HS CODE 9018, 2020–2024      72

5.6           VALUE CHAIN ANALYSIS               72

5.7           ECOSYSTEM ANALYSIS  74

5.7.1        ROLE IN ECOSYSTEM     76

5.8           PORTER’S FIVE FORCES ANALYSIS           77

5.8.1        INTENSITY OF COMPETITIVE RIVALRY 78

5.8.2        BARGAINING POWER OF SUPPLIERS       78

5.8.3        BARGAINING POWER OF BUYERS             78

5.8.4        THREAT OF SUBSTITUTES          78

5.8.5        THREAT OF NEW ENTRANTS      78

5.9           KEY CONFERENCES & EVENTS, 2025–2026              79

5.10         INVESTMENT & FUNDING SCENARIO     80

5.11         IMPACT OF 2025 US TARIFF ON PREIMPLANTATION GENETIC TESTING MARKET       81

5.11.1      KEY TARIFF RATES          81

5.11.2      PRICE IMPACT ANALYSIS             83

5.11.3      KEY IMPACTS ON VARIOUS REGIONS     84

5.11.3.1  US           84

5.11.3.2  Europe   84

5.11.3.3  Asia Pacific            85

5.11.4      END-USE INDUSTRY IMPACT     85

5.11.4.1  Fertility clinics      85

5.11.4.2  Hospitals                85

5.11.4.3  Diagnostic laboratories        86

6               TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 87

6.1           TECHNOLOGY ANALYSIS             87

6.1.1        KEY TECHNOLOGIES     87

6.1.1.1    Laser-assisted TE biopsy    87

6.1.1.2    Whole genome amplification              87

6.1.2        COMPLEMENTARY TECHNOLOGIES       88

6.1.2.1    Micromanipulation               88

6.2           TECHNOLOGY ROADMAP            88

6.3           PATENT ANALYSIS          89

6.3.1        METHODOLOGY              89

6.3.2        NUMBER OF PATENTS FILED, BY DOCUMENT TYPE                 89

6.3.3        LIST OF KEY PATENTS   91

6.4           FUTURE APPLICATIONS               91

6.5           IMPACT OF AI/GEN AI ON PREIMPLANTATION GENETIC TESTING MARKET       92

6.5.1        TOP USE CASES AND MARKET POTENTIAL          93

6.5.2        BEST PRACTICES IN AI-ENABLED EMBRYO SELECTION AND GENETIC SCREENING          94

6.5.3        CASE STUDIES OF AI IMPLEMENTATION IN PREIMPLANTATION GENETIC TESTING MARKET             94

6.5.4        INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS  95

6.5.5        CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PREIMPLANTATION GENETIC TESTING MARKET             95

7               SUSTAINABILITY & REGULATORY LANDSCAPE 96

7.1           REGIONAL REGULATIONS & COMPLIANCE          96

7.1.1        REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS             96

7.1.2        INDUSTRY STANDARDS                99

7.1.2.1    North America      99

7.1.2.1.1 US           99

7.1.2.1.2 Canada   101

7.1.2.2    Europe   102

7.1.2.3    Asia Pacific            104

7.1.2.3.1 Japan      104

7.1.2.3.2 China      106

7.1.2.3.3 India       106

7.1.2.4    Latin America       107

7.1.2.4.1 Brazil      107

7.2           SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES       108

7.3           CERTIFICATIONS, LABELING, AND ECO-STANDARDS                 109

8               CUSTOMER LANDSCAPE & BUYER BEHAVIOUR 110

8.1           DECISION-MAKING PROCESS     110

8.2           BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA             110

8.2.1        KEY STAKEHOLDERS IN BUYING PROCESS           110

8.2.2        KEY BUYING CRITERIA  111

8.3           ADOPTION BARRIERS & INTERNAL CHALLENGES                 113

8.4           UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES                 113

9               PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE    114

9.1           INTRODUCTION              115

9.2           REAGENTS & CONSUMABLES     115

9.2.1        EXPANSION OF ADVANCED GENOMIC TECHNOLOGIES TO PROMOTE MARKET GROWTH            115

9.3           INSTRUMENTS 119

9.3.1        ONGOING TECHNOLOGICAL ADVANCEMENTS AND INCREASING FERTILITY CLINICS TO PROPEL MARKET GROWTH                 119

9.4           SOFTWARE & SERVICES 123

9.4.1        RISING AWARENESS ABOUT DATA ANALYSIS TO DRIVE MARKET               123

10            PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE          128

10.1         INTRODUCTION              129

10.2         PREIMPLANTATION GENETIC SCREENING          129

10.2.1      INCREASING MATERNAL AGE TO AID MARKET GROWTH             129

10.3         PREIMPLANTATION GENETIC DIAGNOSIS           133

10.3.1      RISING AWARENESS ABOUT CHROMOSOMAL ABNORMALITIES IN FETUSES TO SUPPORT MARKET GROWTH                 133

11            PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY  138

11.1         INTRODUCTION              139

11.2         NEXT-GENERATION SEQUENCING          139

11.2.1      IMPROVED TECHNOLOGY FOR DETECTING STRUCTURAL ABNORMALITIES TO FUEL MARKET GROWTH                 139

11.3         POLYMERASE CHAIN REACTION               143

11.3.1      INCREASED USAGE IN CLINICAL AND RESEARCH APPLICATIONS AND HIGH PREVALENCE OF GENETIC DISEASES TO SUPPORT MARKET  143

11.4         FLUORESCENCE IN SITU HYBRIDIZATION           147

11.4.1      ADVANCES IN FLUORESCENCE MICROSCOPY AND DIGITAL IMAGING TO AUGMENT MARKET GROWTH     147

11.5         COMPARATIVE GENOMIC HYBRIDIZATION        151

11.5.1      LOW COST, LESS LABOR REQUIREMENT, AND ONGOING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET               151

11.6         SINGLE-NUCLEOTIDE POLYMORPHISM                155

11.6.1      HIGH-RESOLUTION ACCURACY AND VALIDATED CLINICAL PERFORMANCE TO BOOST MARKET GROWTH                 155

12            PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION   160

12.1         INTRODUCTION              161

12.2         ANEUPLOIDY    161

12.2.1      HIGH ANEUPLOIDY INCIDENCE AND RAPID INNOVATION TO ACCELERATE MARKET GROWTH         161

12.3         STRUCTURAL CHROMOSOMAL ABNORMALITIES                 165

12.3.1      TRANSLOCATIONS          169

12.3.1.1  Rising incidence of translocation chromosomal abnormalities during IVF treatments to drive segment           169

12.3.2      DELETIONS        173

12.3.2.1  Advancements in genetic testing to boost segment growth                 173

12.3.3      DUPLICATIONS                177

12.3.3.1  Rising cases of duplication of chromosomal abnormalities and increasing maternal age to drive segment         177

12.3.4      INVERSIONS       181

12.3.4.1  Risk of unexplained male‐factor infertility and multiple miscarriages to limit segment growth                181

12.4         SINGLE GENE DISORDERS           185

12.4.1      INCREASING AWARENESS ABOUT GENETIC TESTING TO PROPEL MARKET GROWTH 185

12.5         X-LINKED DISORDERS  189

12.5.1      MEDICAL ADVANCEMENTS AND INCREASED RESEARCH ON GENETIC DISORDERS TO AUGMENT MARKET GROWTH                 189

12.6         HLA TYPING      193

12.6.1      RISING NUMBER OF COUPLES WITH CHILDREN AFFECTED BY HEMATOLOGICAL DISEASES TO DRIVE MARKET                 193

12.7         GENDER IDENTIFICATION          197

12.7.1      INCREASED FOCUS ON SEX DISCRIMINATION TO LIMIT MARKET GROWTH          197

13            PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE                 202

13.1         INTRODUCTION              203

13.2         FRESH NON-DONOR      203

13.2.1      HIGH RATES OF SUCCESSFUL PREGNANCY AMONG YOUNG WOMEN TO DRIVE MARKET GROWTH  203

13.3         FROZEN NON-DONOR   207

13.3.1      LONG-TERM STORAGE OF FROZEN EGGS AND EASY SCHEDULING

TO PROPEL MARKET GROWTH 207

13.4         FRESH DONOR  211

13.4.1      HIGH-QUALITY FRESH DONOR OOCYTES AND EXPANDING PGT-DRIVEN RISK REDUCTION TO PROMOTE MARKET GROWTH          211

13.5         FROZEN DONOR               215

13.5.1      RISING USE OF ADVANCED AND NON-INVASIVE PGT TECHNOLOGIES

TO AID MARKET GROWTH          215

14            PREIMPLANTATION GENETIC TESTING MARKET, BY END USER            220

14.1         INTRODUCTION              221

14.2         FERTILITY CLINICS         221

14.2.1      HIGH SUCCESS RATE OF FERTILITY TREATMENT TO DRIVE MARKET 221

14.3         DIAGNOSTIC LABORATORIES    225

14.3.1      IMPROVED CLINICAL EFFICACY AND INCREASED RESEARCH FUNDING TO FUEL MARKET                225

14.4         HOSPITALS         229

14.4.1      RISING NUMBER OF HOSPITALS AND INCREASING HEALTHCARE AWARENESS TO DRIVE GROWTH                229

14.5         OTHER END USERS         233

15            PREIMPLANTATION GENETIC TESTING MARKET, BY REGION                238

15.1         INTRODUCTION              239

15.2         NORTH AMERICA             239

15.2.1      US           244

15.2.1.1  US to dominate North American preimplantation genetic testing market during forecast period             244

15.2.2      CANADA               248

15.2.2.1  Whole-genome embryo testing and public-private R&D investment to propel market growth 248

15.3         EUROPE               252

15.3.1      GERMANY           257

15.3.1.1  Global clinical adoption of precision medicines to boost market growth    257

15.3.2      UK          261

15.3.2.1  Demographic pressures and evidence-based clinical innovation to support market growth    261

15.3.3      FRANCE                265

15.3.3.1  Ethical regulation and adoption of patient-centered precision medicines to fuel market growth        265

15.3.4      ITALY    268

15.3.4.1  Regulatory reforms and clinical-genetic partnerships to boost market growth       268

15.3.5      SPAIN    272

15.3.5.1  Well-established network of research centers and universities to augment market growth      272

15.3.6      REST OF EUROPE             276

15.4         ASIA PACIFIC     280

15.4.1      CHINA  285

15.4.1.1  Advancing next-generation genomic infrastructure and cross-border fertility capacity to propel market growth            285

15.4.2      JAPAN   289

15.4.2.1  Reinforcing global PGT standards and rigorous clinical governance to favor market growth   289

15.4.3      INDIA    293

15.4.3.1  Expanding genetic-diagnostic access to drive market growth                 293

15.4.4      AUSTRALIA         297

15.4.4.1  Standardized regulation and expanding clinical adoption to fuel market growth       297

15.4.5      SOUTH KOREA  301

15.4.5.1  Clinically validated PGT-A integration and improved IVF outcomes to support market growth  301

15.4.6      REST OF ASIA PACIFIC   305

15.5         LATIN AMERICA                309

15.5.1      BRAZIL 313

15.5.1.1  Global genomic innovation and regulatory modernization to boost market growth             313

15.5.2      MEXICO                317

15.5.2.1  Adoption of advanced NGS-based PGT services to support growth    317

15.5.3      REST OF LATIN AMERICA             321

15.6         MIDDLE EAST   325

15.6.1      GCC COUNTRIES              329

15.6.1.1  Kingdom of Saudi Arabia    334

15.6.1.1.1                Rising global emphasis on preventive genomic medicine and advanced embryo-screening technologies to drive market     334

15.6.1.2  UAE        338

15.6.1.2.1                Rising global demand for safer and technologically advanced embryo screening to aid market growth          338

15.6.1.3  Rest of GCC Countries        342

15.6.2      REST OF MIDDLE EAST 345

15.7         AFRICA 349

15.7.1      REGIONAL ART REGISTRY EXPANSION AND RISING IVF INFRASTRUCTURE TO PROPEL MARKET GROWTH          349

16            COMPETITIVE LANDSCAPE         354

16.1         INTRODUCTION              354

16.2         OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET       354

16.3         REVENUE ANALYSIS, 2020–2024  355

16.4         MARKET SHARE ANALYSIS, 2024                 356

16.5         COMPANY VALUATION & FINANCIAL METRICS 358

16.5.1      FINANCIAL METRICS      358

16.5.2      COMPANY VALUATION 358

16.6         BRAND/PRODUCT COMPARISON             359

16.6.1      ILLUMINA, INC. 360

16.6.2      THERMO FISHER SCIENTIFIC INC.            360

16.6.3      AGILENT TECHNOLOGIES, INC.                360

16.7         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 360

16.7.1      STARS   360

16.7.2      EMERGING LEADERS     360

16.7.3      PERVASIVE PLAYERS      361

16.7.4      PARTICIPANTS 361

16.7.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         362

16.7.5.1  Company footprint               362

16.7.5.2  Region footprint   363

16.7.5.3  Product & service footprint 363

16.7.5.4  Technology footprint           364

16.7.5.5  Application footprint            365

16.8         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        366

16.8.1      PROGRESSIVE COMPANIES         366

16.8.2      RESPONSIVE COMPANIES            366

16.8.3      DYNAMIC COMPANIES  366

16.8.4      STARTING BLOCKS         366

16.8.5      COMPETITIVE BENCHMARKING               368

16.8.5.1  Detailed list of key startups/SMEs    368

16.8.5.2  Competitive benchmarking of key startups/SMEs          370

16.9         COMPETITIVE SCENARIO             371

16.9.1      PRODUCT LAUNCHES   371

16.9.2      DEALS  371

16.9.3      EXPANSIONS     372

17            COMPANY PROFILES      373

17.1         KEY PLAYERS     373

17.1.1      ILLUMINA, INC. 373

17.1.1.1  Business overview 373

17.1.1.2  Products/Services/Solutions offered 374

17.1.1.3  Recent developments           375

17.1.1.3.1                Deals      375

17.1.1.4  MnM view              375

17.1.1.4.1                Key strengths        375

17.1.1.4.2                Strategic choices   375

17.1.1.4.3                Weaknesses & competitive threats     375

17.1.2      THERMO FISHER SCIENTIFIC INC.            376

17.1.2.1  Business overview 376

17.1.2.2  Products/Services/Solutions offered 377

17.1.2.3  Recent developments           378

17.1.2.3.1                Product launches  378

17.1.2.4  MnM view              378

17.1.2.4.1                Key strengths        378

17.1.2.4.2                Strategic choices   378

17.1.2.4.3                Weaknesses & competitive threats     378

17.1.3      AGILENT TECHNOLOGIES, INC.                379

17.1.3.1  Business overview 379

17.1.3.2  Products/Services/Solutions offered 380

17.1.3.3  MnM view              381

17.1.3.3.1                Key strengths        381

17.1.3.3.2                Strategic choices   381

17.1.3.3.3                Weaknesses & competitive threats     381

17.1.4      REVVITY               382

17.1.4.1  Business overview 382

17.1.4.2  Products/Services/Solutions offered 383

17.1.4.3  MnM view              384

17.1.4.3.1                Key strengths        384

17.1.4.3.2                Strategic choices   384

17.1.4.3.3                Weaknesses & competitive threats     384

17.1.5      COOPERCOMPANIES     385

17.1.5.1  Business overview 385

17.1.5.2  Products/Services/Solutions offered 386

17.1.5.3  MnM view              387

17.1.5.3.1                Key strengths        387

17.1.5.3.2                Strategic choices   387

17.1.5.3.3                Weaknesses & competitive threats     387

17.1.6      ABBOTT               388

17.1.6.1  Business overview 388

17.1.6.2  Products/Services/Solutions offered 389

17.1.7      TAKARA BIO INC.             390

17.1.7.1  Business overview 390

17.1.7.2  Products/Services/Solutions offered 391

17.1.8      QIAGEN                392

17.1.8.1  Business overview 392

17.1.8.2  Products/Services/Solutions offered 393

17.1.9      VITROLIFE          394

17.1.9.1  Business overview 394

17.1.9.2  Products/Services/Solutions offered 395

17.1.10   OXFORD NANOPORE TECHNOLOGIES PLC          396

17.1.10.1                 Business overview 396

17.1.10.2                 Products/Services/Solutions offered 397

17.1.10.3                 Recent developments           398

17.1.10.3.1             Expansions             398

17.2         OTHER PLAYERS              398

17.2.1      OXFORD GENE TECHNOLOGY IP LIMITED          398

17.2.2      YIKON GENOMICS           399

17.2.3      SHIVA SCIENTIFIC           399

17.2.4      NANJING SUPERYEARS GENE TECHNOLOGY CO., LTD.                 400

17.2.5      MEDICOVER GENETICS 400

17.2.6      MEDGENOME   401

17.2.7      FULGENT GENETICS      401

17.2.8      INVICTA SP. Z O.O.          402

17.2.9      GENEA PTY LIMITED     402

17.2.10   SCIGENE CORPORATION              403

17.2.11   BIOARRAY S.L.   403

17.2.12   UNIMED BIOTECH (SHANGHAI) CO., LTD.           404

17.2.13   GENEMIND BIOSCIENCES CO., LTD.        404

17.2.14   BERRY GENOMICS           405

17.2.15   BANGKOK GENOMICS INNOVATION      405

18            APPENDIX           406

18.1         DISCUSSION GUIDE        406

18.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                411

18.3         CUSTOMIZATION OPTIONS        413

18.4         RELATED REPORTS         413

18.5         AUTHOR DETAILS           414

LIST OF TABLES

TABLE 1                PREIMPLANTATION GENETIC TESTING MARKET: INCLUSIONS & EXCLUSIONS   38

TABLE 2                PREIMPLANTATION GENETIC TESTING MARKET: IMPACT ANALYSIS

OF MARKET DYNAMICS                55

TABLE 3                AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY END USER, 2022−2024 (USD) 65

TABLE 4                AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)              65

TABLE 5                AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY PROCEDURE TYPE, 2022−2024 (USD)     67

TABLE 6                AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS, BY REGION, 2022–2024 (USD MILLION)          67

TABLE 7                AVERAGE SELLING PRICE MEAN TREND OF PREIMPLANTATION GENETIC TESTING CONSUMABLES, BY REGION, 2022–2024 (USD)             67

TABLE 8               IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND)      69

TABLE 9               EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND)      70

TABLE 10             IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2020–2024 (USD THOUSAND)      71

TABLE 11             EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2020–2024 (USD THOUSAND)      72

TABLE 12              PREIMPLANTATION GENETIC TESTING MARKET: ROLE IN ECOSYSTEM 76

TABLE 13              PREIMPLANTATION GENETIC TESTING MARKET: PORTER’S FIVE FORCES             77

TABLE 14              KEY CONFERENCES & EVENTS IN PREIMPLANTATION GENETIC TESTING MARKET: JANUARY 2025–DECEMBER 2026     79

TABLE 15              US-ADJUSTED RECIPROCAL TARIFF RATES                 81

TABLE 16              NUMBER OF EXPORTS AND IMPORTS, BY REGION, 2024–2025 (USD MILLION)          82

TABLE 17              KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT

TO PREIMPLANTATION GENETIC TESTING        83

TABLE 18              CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES            84

TABLE 19              NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024                 89

TABLE 20              LIST OF KEY PATENTS IN PREIMPLANTATION GENETIC TESTING MARKET,

2023–2025              91

TABLE 21              KEY PLAYERS IMPLEMENTING AI/GEN AI IN PREIMPLANTATION GENETIC TESTING MARKET             94

TABLE 22              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 96

TABLE 23              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  97

TABLE 24              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  97

TABLE 25              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  98

TABLE 26              US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES              99

TABLE 27              EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES  102

TABLE 28              JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS              105

TABLE 29              JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS             105

TABLE 30              CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS             106

TABLE 31              VENDOR CERTIFICATIONS: PREIMPLANTATION GENETIC TESTING MARKET             109

TABLE 32              INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,

BY PRODUCT & SERVICE               111

TABLE 33              KEY BUYING CRITERIA FOR MAJOR END USERS                 112

TABLE 34              PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE,

2023–2030 (USD MILLION)            115

TABLE 35              PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET,

BY REGION, 2023–2030 (USD MILLION)   116

TABLE 36              NORTH AMERICA: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     116

TABLE 37              EUROPE: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            117

TABLE 38              ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            117

TABLE 39              LATIN AMERICA: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            118

TABLE 40              MIDDLE EAST: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)            118

TABLE 41              GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     119

TABLE 42              PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            120

TABLE 43              NORTH AMERICA: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            120

TABLE 44              EUROPE: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               121

TABLE 45              ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               121

TABLE 46              LATIN AMERICA: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               122

TABLE 47              MIDDLE EAST: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET,

BY REGION, 2023–2030 (USD MILLION)   122

TABLE 48              GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            123

TABLE 49              PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET,

BY REGION, 2023–2030 (USD MILLION)   124

TABLE 50              NORTH AMERICA: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     124

TABLE 51              EUROPE: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       125

TABLE 52              ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       125

TABLE 53              LATIN AMERICA: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       126

TABLE 54              MIDDLE EAST: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)       126

TABLE 55              GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     127

TABLE 56              PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE,

2023–2030 (USD MILLION)            129

TABLE 57              PREIMPLANTATION GENETIC SCREENING MARKET, BY REGION,

2023–2030 (USD MILLION)            130

TABLE 58              NORTH AMERICA: PREIMPLANTATION GENETIC SCREENING MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               130

TABLE 59              EUROPE: PREIMPLANTATION GENETIC SCREENING MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            131

TABLE 60              ASIA PACIFIC: PREIMPLANTATION GENETIC SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 131

TABLE 61              LATIN AMERICA: PREIMPLANTATION GENETIC SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 132

TABLE 62              MIDDLE EAST: PREIMPLANTATION GENETIC SCREENING MARKET, BY REGION, 2023–2030 (USD MILLION)                 132

TABLE 63              GCC COUNTRIES: PREIMPLANTATION GENETIC SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            133

TABLE 64              PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY REGION,

2023–2030 (USD MILLION)            134

TABLE 65              NORTH AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            134

TABLE 66              EUROPE: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            135

TABLE 67              ASIA PACIFIC: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 135

TABLE 68              LATIN AMERICA: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 136

TABLE 69              MIDDLE EAST: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY REGION, 2023–2030 (USD MILLION)                 136

TABLE 70              GCC COUNTRIES: PREIMPLANTATION GENETIC DIAGNOSIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            137

TABLE 71              PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            139

TABLE 72              PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)            140

TABLE 73              NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR

NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 140

TABLE 74              EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)     141

TABLE 75              ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)     141

TABLE 76              LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR

NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 142

TABLE 77              MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)          142

TABLE 78              GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR

NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 143

TABLE 79              PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)            144

TABLE 80              NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)      144

TABLE 81              EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)     145

TABLE 82              ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)     145

TABLE 83              LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)     146

TABLE 84              MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)          146

TABLE 85              GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)      147

TABLE 86              PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION)          148

TABLE 87              NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 88              EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION)                 149

TABLE 89              ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION)                 149

TABLE 90              LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 91              MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION)                 150

TABLE 92              GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY,

2023–2030 (USD MILLION)            151

TABLE 93              PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION)          152

TABLE 94              NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 95              EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION)                 153

TABLE 96              ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION)                 153

TABLE 97              LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY,

2023–2030 (USD MILLION)            154

TABLE 98              MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION)                 154

TABLE 99              GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY,

2023–2030 (USD MILLION)            155

TABLE 100            PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2023–2030 (USD MILLION)          156

TABLE 101            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION)                 156

TABLE 102            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION)               157

TABLE 103            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION)               157

TABLE 104            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION)               158

TABLE 105            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2023–2030 (USD MILLION)   158

TABLE 106            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2023–2030 (USD MILLION)                 159

TABLE 107            PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            161

TABLE 108            PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY REGION, 2023–2030 (USD MILLION)            162

TABLE 109            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY COUNTRY, 2023–2030 (USD MILLION)            163

TABLE 110            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 111            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY,

BY COUNTRY, 2023–2030 (USD MILLION)               164

TABLE 112            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET

FOR ANEUPLOIDY, BY COUNTRY, 2023–2030 (USD MILLION)                 164

TABLE 113            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET

FOR ANEUPLOIDY, BY REGION, 2023–2030 (USD MILLION)                 165

TABLE 114            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET

FOR ANEUPLOIDY, BY COUNTRY, 2023–2030 (USD MILLION)                 165

TABLE 115            PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL

CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)            166

TABLE 116            PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL

CHROMOSOMAL ABNORMALITIES, BY REGION, 2023–2030 (USD MILLION)            166

TABLE 117            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY,

2023–2030 (USD MILLION)            167

TABLE 118            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION)                 167

TABLE 119            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION)                 168

TABLE 120            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION)                 168

TABLE 121            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2023–2030 (USD MILLION)                 169

TABLE 122            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY,

2023–2030 (USD MILLION)            169

TABLE 123            STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR

TRANSLOCATIONS, BY REGION, 2023–2030 (USD MILLION)                 170

TABLE 124            NORTH AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            170

TABLE 125            EUROPE: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     171

TABLE 126            ASIA PACIFIC: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            171

TABLE 127            LATIN AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            172

TABLE 128            MIDDLE EAST: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            172

TABLE 129            GCC COUNTRIES: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR TRANSLOCATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            173

TABLE 130            STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DELETIONS,

BY REGION, 2023–2030 (USD MILLION)   174

TABLE 131            NORTH AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 174

TABLE 132            EUROPE: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION)            175

TABLE 133            ASIA PACIFIC: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 175

TABLE 134            LATIN AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 176

TABLE 135            MIDDLE EAST: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 176

TABLE 136            GCC COUNTRIES: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DELETIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 177

TABLE 137            STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR DUPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   178

TABLE 138            NORTH AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 178

TABLE 139            EUROPE: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 179

TABLE 140            ASIA PACIFIC: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 179

TABLE 141            LATIN AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 180

TABLE 142            MIDDLE EAST: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 180

TABLE 143            GCC COUNTRIES: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR DUPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 181

TABLE 144            STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET FOR INVERSIONS,

BY REGION, 2023–2030 (USD MILLION)   182

TABLE 145            NORTH AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 182

TABLE 146            EUROPE: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 183

TABLE 147            ASIA PACIFIC: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 183

TABLE 148            LATIN AMERICA: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION)     184

TABLE 149            MIDDLE EAST: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 184

TABLE 150            GCC COUNTRIES: STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET

FOR INVERSIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 185

TABLE 151            PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS,

BY REGION, 2023–2030 (USD MILLION)   186

TABLE 152            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     186

TABLE 153            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            187

TABLE 154            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            187

TABLE 155            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            188

TABLE 156            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY REGION, 2023–2030 (USD MILLION)            188

TABLE 157            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     189

TABLE 158            PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS,

BY REGION, 2023–2030 (USD MILLION)   190

TABLE 159            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     190

TABLE 160            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            191

TABLE 161            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            191

TABLE 162            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            192

TABLE 163            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            192

TABLE 164            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     193

TABLE 165            PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY REGION, 2023–2030 (USD MILLION)            194

TABLE 166            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY COUNTRY, 2023–2030 (USD MILLION)            194

TABLE 167            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING,

BY COUNTRY, 2023–2030 (USD MILLION)               195

TABLE 168            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING,

BY COUNTRY, 2023–2030 (USD MILLION)               195

TABLE 169            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY COUNTRY, 2023–2030 (USD MILLION) 196

TABLE 170            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING,

BY COUNTRY, 2023–2030 (USD MILLION)               196

TABLE 171            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR HLA TYPING, BY COUNTRY, 2023–2030 (USD MILLION)            197

TABLE 172            PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION,

BY REGION, 2023–2030 (USD MILLION)   198

TABLE 173            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)     198

TABLE 174            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)     199

TABLE 175            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)     199

TABLE 176            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)     200

TABLE 177            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)     200

TABLE 178            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)     201

TABLE 179            PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)            203

TABLE 180            PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONOR,

BY REGION, 2023–2030 (USD MILLION)   204

TABLE 181            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH

NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 204

TABLE 182            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION)            205

TABLE 183            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH

NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 205

TABLE 184            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH

NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 206

TABLE 185            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH

NON-DONOR, BY REGION, 2023–2030 (USD MILLION)     206

TABLE 186            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH

NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 207

TABLE 187            PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR,

BY REGION, 2023–2030 (USD MILLION)   208

TABLE 188            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION)     208

TABLE 189            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN

NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 209

TABLE 190            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN

NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 209

TABLE 191            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN

NON-DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 210

TABLE 192            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN

NON-DONOR, BY REGION, 2023–2030 (USD MILLION)     210

TABLE 193            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN NON-DONOR, SBY COUNTRY, 2023–2030 (USD MILLION)     211

TABLE 194            PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY REGION, 2023–2030 (USD MILLION)            212

TABLE 195            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY COUNTRY, 2023–2030 (USD MILLION)            212

TABLE 196            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR,

BY COUNTRY, 2023–2030 (USD MILLION)               213

TABLE 197            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 213

TABLE 198            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY COUNTRY, 2023–2030 (USD MILLION) 214

TABLE 199            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY REGION, 2023–2030 (USD MILLION) 214

TABLE 200            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FRESH DONOR, BY COUNTRY, 2023–2030 (USD MILLION)            215

TABLE 201            PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY REGION, 2023–2030 (USD MILLION)            216

TABLE 202            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY COUNTRY, 2023–2030 (USD MILLION)     216

TABLE 203            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR,

BY COUNTRY, 2023–2030 (USD MILLION)               217

TABLE 204            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY COUNTRY, 2023–2030 (USD MILLION)       217

TABLE 205            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY COUNTRY, 2023–2030 (USD MILLION)       218

TABLE 206            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY REGION, 2023–2030 (USD MILLION) 218

TABLE 207            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FROZEN DONOR, BY COUNTRY, 2023–2030 (USD MILLION)     219

TABLE 208            PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            221

TABLE 209            PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS,

BY REGION, 2023–2030 (USD MILLION)   222

TABLE 210            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)     222

TABLE 211            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)       223

TABLE 212            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)       223

TABLE 213            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)       224

TABLE 214            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY REGION, 2023–2030 (USD MILLION)       224

TABLE 215            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)     225

TABLE 216            PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)       226

TABLE 217            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)               226

TABLE 218            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     227

TABLE 219            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     227

TABLE 220            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     228

TABLE 221            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)          228

TABLE 222            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)               229

TABLE 223            PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)            230

TABLE 224            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)            230

TABLE 225            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS,

BY COUNTRY, 2023–2030 (USD MILLION)               231

TABLE 226            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS,

BY COUNTRY, 2023–2030 (USD MILLION)               231

TABLE 227            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 232

TABLE 228            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS,

BY REGION, 2023–2030 (USD MILLION)   232

TABLE 229            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)            233

TABLE 230            PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS,

BY REGION, 2023–2030 (USD MILLION)   234

TABLE 231            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR

OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)                 234

TABLE 232            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)       235

TABLE 233            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER

END USERS, BY COUNTRY, 2023–2030 (USD MILLION)     235

TABLE 234            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER

END USERS, BY COUNTRY, 2023–2030 (USD MILLION)     236

TABLE 235            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR OTHER

END USERS, BY REGION, 2023–2030 (USD MILLION)          236

TABLE 236            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR

OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)                 237

TABLE 237            PREIMPLANTATION GENETIC TESTING MARKET, BY REGION,

2023–2030 (USD MILLION)            239

TABLE 238            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               240

TABLE 239            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        241

TABLE 240            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY PROCEDURE TYPE, 2023–2030 (USD MILLION)              241

TABLE 241            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     242

TABLE 242            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       242

TABLE 243            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE,

2023–2030 (USD MILLION)            243

TABLE 244            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   243

TABLE 245            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               244

TABLE 246            US: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 245

TABLE 247            US: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE,

2023–2030 (USD MILLION)            245

TABLE 248            US: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            246

TABLE 249            US: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            246

TABLE 250            US: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)         247

TABLE 251            US: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)          247

TABLE 252            US: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            248

TABLE 253            CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            249

TABLE 254            CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            249

TABLE 255            CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            250

TABLE 256            CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            250

TABLE 257            CANADA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    251

TABLE 258            CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION)            251

TABLE 259            CANADA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            252

TABLE 260            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            253

TABLE 261            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            253

TABLE 262            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            254

TABLE 263            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            254

TABLE 264            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            255

TABLE 265            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    255

TABLE 266            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   256

TABLE 267            EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            256

TABLE 268            GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            257

TABLE 269            GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            258

TABLE 270            GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)                 258

TABLE 271            GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)                 259

TABLE 272            GERMANY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    259

TABLE 273            GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION)            260

TABLE 274            GERMANY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            260

TABLE 275            UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 261

TABLE 276            UK: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE,

2023–2030 (USD MILLION)            262

TABLE 277            UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            262

TABLE 278            UK: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            263

TABLE 279            UK: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)         263

TABLE 280            UK: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)            264

TABLE 281            UK: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            264

TABLE 282            FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT &

SERVICE, 2023–2030 (USD MILLION)         265

TABLE 283            FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            266

TABLE 284            FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            266

TABLE 285            FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            267

TABLE 286            FRANCE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    267

TABLE 287            FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION)            268

TABLE 288            FRANCE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            268

TABLE 289            ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 269

TABLE 290            ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)                 269

TABLE 291            ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)          270

TABLE 292            ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            270

TABLE 293            ITALY: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)         271

TABLE 294            ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)            271

TABLE 295            ITALY: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            272

TABLE 296            SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 273

TABLE 297            SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)                 273

TABLE 298            SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)          274

TABLE 299            SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            274

TABLE 300            SPAIN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)         275

TABLE 301            SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)            275

TABLE 302            SPAIN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            276

TABLE 303            REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 277

TABLE 304            REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION) 277

TABLE 305            REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     278

TABLE 306            REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       278

TABLE 307            REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE,

2023–2030 (USD MILLION)            279

TABLE 308            REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   279

TABLE 309            REST OF EUROPE: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               280

TABLE 310            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 282

TABLE 311            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            282

TABLE 312            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            283

TABLE 313            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)                 283

TABLE 314            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)                 284

TABLE 315            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    284

TABLE 316            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION)            285

TABLE 317            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION)                 285

TABLE 318            CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 286

TABLE 319            CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)                 286

TABLE 320            CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            287

TABLE 321            CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            287

TABLE 322            CHINA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)         288

TABLE 323            CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)            288

TABLE 324            CHINA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            289

TABLE 325            JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 290

TABLE 326            JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)                 290

TABLE 327            JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            291

TABLE 328            JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            291

TABLE 329            JAPAN: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)         292

TABLE 330            JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)            292

TABLE 331            JAPAN: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            293

TABLE 332            INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 294

TABLE 333            INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)                 294

TABLE 334            INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)          295

TABLE 335            INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            295

TABLE 336            INDIA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)         296

TABLE 337            INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)            296

TABLE 338            INDIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            297

TABLE 339            AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            298

TABLE 340            AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            298

TABLE 341            AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)                 299

TABLE 342            AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)                 299

TABLE 343            AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    300

TABLE 344            AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION)            300

TABLE 345            AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            301

TABLE 346            SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            302

TABLE 347            SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            302

TABLE 348            SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)                 303

TABLE 349            SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)                 303

TABLE 350            SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    304

TABLE 351            SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION)            304

TABLE 352            SOUTH KOREA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030 (USD MILLION)                 305

TABLE 353            REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        306

TABLE 354            REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET,

BY PROCEDURE TYPE, 2023–2030 (USD MILLION)              306

TABLE 355            REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     307

TABLE 356            REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       307

TABLE 357            REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE,

2023–2030 (USD MILLION)            308

TABLE 358            REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   308

TABLE 359            REST OF ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               309

TABLE 360            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 309

TABLE 361            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            310

TABLE 362            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            310

TABLE 363            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)                 311

TABLE 364            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)                 311

TABLE 365            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    312

TABLE 366            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   312

TABLE 367            LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               313

TABLE 368            BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT &

SERVICE, 2023–2030 (USD MILLION)         314

TABLE 369            BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)                 314

TABLE 370            BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            315

TABLE 371            BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            315

TABLE 372            BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)         316

TABLE 373            BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)            316

TABLE 374            BRAZIL: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            317

TABLE 375            MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            318

TABLE 376            MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            318

TABLE 377            MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            319

TABLE 378            MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            319

TABLE 379            MEXICO: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    320

TABLE 380            MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE, 2023–2030 (USD MILLION)            320

TABLE 381            MEXICO: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            321

TABLE 382            REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        322

TABLE 383            REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY PROCEDURE TYPE, 2023–2030 (USD MILLION)              322

TABLE 384            REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     323

TABLE 385            REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       323

TABLE 386            REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE,

2023–2030 (USD MILLION)            324

TABLE 387            REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   324

TABLE 388            REST OF LATIN AMERICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               325

TABLE 389            MIDDLE EAST: KEY MACROINDICATORS                 325

TABLE 390            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY REGION,

2023–2030 (USD MILLION)            326

TABLE 391            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)            326

TABLE 392            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE, 2023–2030 (USD MILLION)            327

TABLE 393            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)                 327

TABLE 394            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)                 328

TABLE 395            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    328

TABLE 396            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   329

TABLE 397            MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               329

TABLE 398            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               330

TABLE 399            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        330

TABLE 400            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY PROCEDURE TYPE, 2023–2030 (USD MILLION)              331

TABLE 401            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     331

TABLE 402            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)     332

TABLE 403            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE,

2023–2030 (USD MILLION)            332

TABLE 404            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   333

TABLE 405            GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)             333

TABLE 406            KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        334

TABLE 407            KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET,

BY PROCEDURE TYPE, 2023–2030 (USD MILLION)              335

TABLE 408            KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     335

TABLE 409            KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       336

TABLE 410            KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE,

2023–2030 (USD MILLION)            336

TABLE 411            KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   337

TABLE 412            KINGDOM OF SAUDI ARABIA: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               337

TABLE 413            UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)                 338

TABLE 414            UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE,

2023–2030 (USD MILLION)            339

TABLE 415            UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            339

TABLE 416            UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            340

TABLE 417            UAE: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)         340

TABLE 418            UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2023–2030 (USD MILLION)          341

TABLE 419            UAE: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2023–2030 (USD MILLION)            341

TABLE 420            REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        342

TABLE 421            REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY PROCEDURE TYPE, 2023–2030 (USD MILLION)              343

TABLE 422            REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     343

TABLE 423            REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       344

TABLE 424            REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE,

2023–2030 (USD MILLION)            344

TABLE 425            REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   345

TABLE 426            REST OF GCC COUNTRIES: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               345

TABLE 427            REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        346

TABLE 428            REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET,

BY PROCEDURE TYPE, 2023–2030 (USD MILLION)              346

TABLE 429            REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)     347

TABLE 430            REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       347

TABLE 431            REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE,

2023–2030 (USD MILLION)            348

TABLE 432            REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   348

TABLE 433            REST OF MIDDLE EAST: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               349

TABLE 434            AFRICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)        350

TABLE 435            AFRICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY PROCEDURE TYPE, 2023–2030 (USD MILLION)              350

TABLE 436            AFRICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)   351

TABLE 437            AFRICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       351

TABLE 438            AFRICA: PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2023–2030 (USD MILLION)    352

TABLE 439            AFRICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY TYPE OF CYCLE, 2023–2030 (USD MILLION)   352

TABLE 440            AFRICA: PREIMPLANTATION GENETIC TESTING MARKET,

BY END USER, 2023–2030 (USD MILLION)               353

TABLE 441            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET, JANUARY 2022-OCTOBER 2025    354

TABLE 442            PREIMPLANTATION GENETIC TESTING MARKET: DEGREE OF COMPETITION    356

TABLE 443            PREIMPLANTATION GENETIC TESTING MARKET: REGION FOOTPRINT 363

TABLE 444            PREIMPLANTATION GENETIC TESTING MARKET: PRODUCT & SERVICE FOOTPRINT       363

TABLE 445            PREIMPLANTATION GENETIC TESTING MARKET: TECHNOLOGY FOOTPRINT    364

TABLE 446            PREIMPLANTATION GENETIC TESTING MARKET: APPLICATION FOOTPRINT     365

TABLE 447            PREIMPLANTATION GENETIC TESTING MARKET:

DETAILED LIST OF KEY STARTUPS/SMES             368

TABLE 448            PREIMPLANTATION GENETIC TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE AND REGION                 370

TABLE 449            PREIMPLANTATION GENETIC TESTING MARKET: PRODUCT LAUNCHES,

JANUARY 2022–OCTOBER 2025   371

TABLE 450            PREIMPLANTATION GENETIC TESTING MARKET: DEALS,

JANUARY 2022–OCTOBER 2025   371

TABLE 451            PREIMPLANTATION GENETIC TESTING MARKET: EXPANSIONS,

JANUARY 2022–OCTOBER 2025   372

TABLE 452            ILLUMINA, INC.: COMPANY OVERVIEW 373

TABLE 453            ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    374

TABLE 454            ILLUMINA, INC.: DEALS, JANUARY 2022–OCTOBER 2025  375

TABLE 455            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          376

TABLE 456            THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    377

TABLE 457            THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,

JANUARY 2022–OCTOBER 2025   378

TABLE 458            AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW          379

TABLE 459            AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    380

TABLE 460            REVVITY: COMPANY OVERVIEW               382

TABLE 461            REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED             383

TABLE 462            COOPERCOMPANIES: COMPANY OVERVIEW                 385

TABLE 463            COOPERCOMPANIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED    386

TABLE 464            ABBOTT: COMPANY OVERVIEW                388

TABLE 465            ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED             389

TABLE 466            TAKARA BIO INC.: COMPANY OVERVIEW                 390

TABLE 467            TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    391

TABLE 468            QIAGEN: COMPANY OVERVIEW 392

TABLE 469            QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED             393

TABLE 470            VITROLIFE: COMPANY OVERVIEW           394

TABLE 471            VITROLIFE: PRODUCTS/SERVICES/SOLUTIONS OFFERED             395

TABLE 472            OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW   396

TABLE 473            OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES/

SOLUTIONS OFFERED   397

TABLE 474            OXFORD NANOPORE TECHNOLOGIES PLC: EXPANSIONS,

JANUARY 2022–OCTOBER 2025   398

TABLE 475            OXFORD GENE TEHNOLOGY IP LIMITED: COMPANY OVERVIEW   398

TABLE 476            YIKON GENOMICS: COMPANY OVERVIEW                 399

TABLE 477            SHIVA SCIENTIFIC: COMPANY OVERVIEW                 399

TABLE 478            NANJING SUPERYEARS GENE TECHNOLOGY CO., LTD.: COMPANY OVERVIEW              400

TABLE 479            MEDICOVER GENETICS: COMPANY OVERVIEW                 400

TABLE 480            MEDGENOME: COMPANY OVERVIEW    401

TABLE 481            FULGENT GENETICS: COMPANY OVERVIEW                 401

TABLE 482            INVICTA SP. Z O.O.: COMPANY OVERVIEW                 402

TABLE 483            GENEA PTY LIMITED: COMPANY OVERVIEW                 402

TABLE 484            SCIGENE CORPORATION: COMPANY OVERVIEW                 403

TABLE 485            BIOARRAY S.L.: COMPANY OVERVIEW   403

TABLE 486            UNIMED BIOTECH (SHANGHAI) CO., LTD.: COMPANY OVERVIEW   404

TABLE 487            GENEMIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW          404

TABLE 488            BERRY GENOMICS: COMPANY OVERVIEW                 405

TABLE 489            BANGKOK GENOMICS INNOVATION: COMPANY OVERVIEW          405

LIST OF FIGURES

FIGURE 1              PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION &

REGIONAL SCOPE            37

FIGURE 2              PREIMPLANTATION GENETIC TESTING MARKET: YEARS CONSIDERED  38

FIGURE 3              PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE,

2025 VS. 2030 (USD MILLION)      41

FIGURE 4              PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE,

2025 VS. 2030 (USD MILLION)      42

FIGURE 5              PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY,

2025 VS. 2030 (USD MILLION)      43

FIGURE 6              PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION,

2025 VS. 2030 (USD MILLION)      44

FIGURE 7              PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE,

2025 VS. 2030 (USD MILLION)      45

FIGURE 8              PREIMPLANTATION GENETIC TESTING MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      46

FIGURE 9              REGIONAL ANALYSIS: PREIMPLANTATION GENETIC TESTING MARKET       47

FIGURE 10            DECLINING FERTILITY RATES TO PROPEL MARKET GROWTH          50

FIGURE 11            US AND REAGENTS & CONSUMABLES COMMANDED LARGEST

NORTH AMERICAN MARKET SHARE IN 2024         51

FIGURE 12            ASIA PACIFIC TO BE FASTEST-GROWING MARKET FROM 2025 TO 2030       52

FIGURE 13            REAGENTS & CONSUMABLES TO DOMINATE MARKET DURING STUDY PERIOD            53

FIGURE 14            FERTILITY CLINICS ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 53

FIGURE 15            PREIMPLANTATION GENETIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    54

FIGURE 16            PREIMPLANTATION GENETIC TESTING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            62

FIGURE 17            AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS, BY KEY PLAYER, 2024 (USD)        66

FIGURE 18            AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING CONSUMABLES, BY KEY PLAYER, 2024 (USD)        66

FIGURE 19            AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS, BY REGION, 2024 (USD MILLION)    68

FIGURE 20            AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING CONSUMABLES, BY REGION, 2024 (USD MILLION)    68

FIGURE 21            PREIMPLANTATION GENETIC TESTING MARKET: VALUE CHAIN ANALYSIS           73

FIGURE 22            PREIMPLANTATION GENETIC TESTING MARKET: ECOSYSTEM ANALYSIS              75

FIGURE 23            PREIMPLANTATION GENETIC TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS       77

FIGURE 24            FUNDING AND NUMBER OF DEALS IN PREIMPLANTATION GENETIC TESTING MARKET, 2022–2025 (USD MILLION) 80

FIGURE 25            PATENT APPLICATIONS IN PREIMPLANTATION GENETIC TESTING MARKET, JANUARY 2014-DECEMBER 2024                 90

FIGURE 26            IMPACT OF AI/GEN AI ON PREIMPLANTATION GENETIC TESTING MARKET       93

FIGURE 27            US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  100

FIGURE 28            CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  101

FIGURE 29            EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  103

FIGURE 30            JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  104

FIGURE 31            INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  107

FIGURE 32            BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  108

FIGURE 33            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,

BY PRODUCT & SERVICE               110

FIGURE 34            KEY BUYING CRITERIA FOR MAJOR END USERS                 111

FIGURE 35            NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT                240

FIGURE 36            ASIA PACIFIC: PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT   281

FIGURE 37            REVENUE ANALYSIS OF KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET, 2020–2024 (USD MILLION) 355

FIGURE 38            MARKET SHARE ANALYSIS OF KEY PLAYERS IN PREIMPLANTATION

GENETIC TESTING MARKET (2024)          356

FIGURE 39            EV/EBITDA OF KEY VENDORS   358

FIGURE 40            YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                358

FIGURE 41            PREIMPLANTATION GENETIC TESTING MARKET: BRAND/PRODUCT

COMPARATIVE ANALYSIS            359

FIGURE 42            PREIMPLANTATION GENETIC TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024                 361

FIGURE 43            PREIMPLANTATION GENETIC TESTING MARKET: COMPANY FOOTPRINT             362

FIGURE 44            PREIMPLANTATION GENETIC TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024        367

FIGURE 45            ILLUMINA, INC.: COMPANY SNAPSHOT 374

FIGURE 46            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT          377

FIGURE 47            AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT          380

FIGURE 48            REVVITY: COMPANY SNAPSHOT               383

FIGURE 49            COOPERCOMPANIES: COMPANY SNAPSHOT                 386

FIGURE 50            ABBOTT: COMPANY SNAPSHOT                389

FIGURE 51            TAKARA BIO INC.: COMPANY SNAPSHOT                 391

FIGURE 52            QIAGEN: COMPANY SNAPSHOT                 393

FIGURE 53            VITROLIFE: COMPANY SNAPSHOT           395

FIGURE 54            OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT   397

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧